| Primary |
| Epilepsy |
48.3% |
| Convulsion |
13.9% |
| Parkinson's Disease |
9.7% |
| Convulsion Prophylaxis |
3.2% |
| Product Used For Unknown Indication |
3.2% |
| Drug Use For Unknown Indication |
2.6% |
| Migraine |
2.2% |
| Prophylaxis |
2.0% |
| Status Epilepticus |
2.0% |
| Hypertension |
1.6% |
| Upper Respiratory Tract Inflammation |
1.4% |
| Anxiety |
1.3% |
| Partial Seizures |
1.3% |
| Constipation |
1.2% |
| Migraine Prophylaxis |
1.2% |
| Drug Exposure In Utero |
1.1% |
| Overdose |
1.0% |
| Trigeminal Neuralgia |
1.0% |
| Complex Partial Seizures |
0.9% |
| Insomnia |
0.8% |
|
| Stevens-johnson Syndrome |
14.3% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
12.9% |
| Convulsion |
9.6% |
| Toxic Epidermal Necrolysis |
8.4% |
| Product Substitution Issue |
6.7% |
| Therapeutic Response Unexpected With Drug Substitution |
6.5% |
| Vomiting |
4.8% |
| Pyrexia |
4.5% |
| White Blood Cell Count Decreased |
4.2% |
| Agranulocytosis |
3.9% |
| Drug Eruption |
3.4% |
| Calculus Urinary |
3.1% |
| Renal Failure |
2.8% |
| Drug Exposure During Pregnancy |
2.2% |
| Nephrolithiasis |
2.2% |
| Pharmaceutical Product Complaint |
2.2% |
| Weight Decreased |
2.2% |
| Drug Ineffective |
2.0% |
| Renal Colic |
2.0% |
| Status Epilepticus |
2.0% |
|
| Secondary |
| Epilepsy |
45.5% |
| Convulsion |
11.2% |
| Product Used For Unknown Indication |
7.8% |
| Drug Use For Unknown Indication |
7.3% |
| Parkinson's Disease |
5.6% |
| Foetal Exposure During Pregnancy |
2.7% |
| Partial Seizures |
2.5% |
| Infantile Spasms |
2.2% |
| Status Epilepticus |
1.8% |
| Bipolar Disorder |
1.6% |
| Pain |
1.6% |
| Insomnia |
1.5% |
| Schizophrenia |
1.4% |
| Abnormal Behaviour |
1.3% |
| Trigeminal Neuralgia |
1.2% |
| Seizures |
1.1% |
| Tuberous Sclerosis |
1.1% |
| Migraine Prophylaxis |
1.0% |
| Hypertension |
0.9% |
| Ill-defined Disorder |
0.9% |
|
| Renal Colic |
11.3% |
| Vomiting |
10.3% |
| Status Epilepticus |
8.9% |
| Foetal Exposure During Pregnancy |
8.5% |
| Stevens-johnson Syndrome |
7.0% |
| Convulsion |
6.6% |
| Toxic Epidermal Necrolysis |
5.2% |
| Somnolence |
4.7% |
| Malignant Melanoma |
4.2% |
| White Blood Cell Count Decreased |
4.2% |
| Mental Impairment |
3.8% |
| Drug Ineffective |
3.3% |
| Fatigue |
3.3% |
| Rhabdomyolysis |
3.3% |
| Drug Prescribing Error |
2.8% |
| Foot Fracture |
2.8% |
| Hypernatraemia |
2.8% |
| Calculus Urinary |
2.3% |
| Complex Partial Seizures |
2.3% |
| Peritonitis Sclerosing |
2.3% |
|
| Concomitant |
| Epilepsy |
24.9% |
| Product Used For Unknown Indication |
20.1% |
| Convulsion |
8.9% |
| Infantile Spasms |
8.9% |
| Drug Use For Unknown Indication |
4.7% |
| Hiv Infection |
3.3% |
| Lennox-gastaut Syndrome |
3.1% |
| Prophylaxis |
2.8% |
| Parkinson's Disease |
2.4% |
| Pain |
2.3% |
| Hypertension |
2.1% |
| Partial Seizures |
2.1% |
| Complex Partial Seizures |
2.0% |
| Multiple Sclerosis |
1.9% |
| Rheumatoid Arthritis |
1.8% |
| Anxiety |
1.8% |
| Migraine |
1.8% |
| Psoriasis |
1.7% |
| Constipation |
1.7% |
| Schizophrenia |
1.5% |
|
| Convulsion |
13.0% |
| Drug Ineffective |
8.0% |
| Status Epilepticus |
8.0% |
| Initial Insomnia |
6.6% |
| Pyrexia |
5.8% |
| Weight Decreased |
5.6% |
| Death |
5.3% |
| Somnolence |
4.8% |
| Vomiting |
4.8% |
| Grand Mal Convulsion |
4.5% |
| Weight Increased |
4.2% |
| Fall |
4.0% |
| Tremor |
3.7% |
| Ventricular Septal Defect |
3.7% |
| Epilepsy |
3.4% |
| Thirst |
3.4% |
| Rash |
2.9% |
| Suicidal Ideation |
2.9% |
| Pain |
2.7% |
| Stevens-johnson Syndrome |
2.7% |
|
| Interacting |
| Drug Use For Unknown Indication |
30.8% |
| Epilepsy |
26.9% |
| Convulsion |
17.3% |
| Lennox-gastaut Syndrome |
9.6% |
| Grand Mal Convulsion |
5.8% |
| Anaesthesia |
3.8% |
| Partial Seizures |
3.8% |
| Motion Sickness |
1.9% |
|
| Drug Interaction |
21.1% |
| Drug Toxicity |
21.1% |
| Hepatic Steatosis |
21.1% |
| Mutism |
10.5% |
| Drug Level Increased |
5.3% |
| Epilepsy |
5.3% |
| Postictal State |
5.3% |
| Somnolence |
5.3% |
| Status Epilepticus |
5.3% |
|
